GZ17-6.02 in Advanced Castration-Resistant Prostate Cancer (CRPC) After Progression on Anti-Androgen Therapy
Latest Information Update: 12 Dec 2024
Price :
$35 *
At a glance
- Drugs GZ17-6.02 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 09 Dec 2024 Planned End Date changed from 30 Sep 2031 to 31 Oct 2031.
- 09 Dec 2024 Planned primary completion date changed from 31 Mar 2027 to 30 Apr 2027.
- 09 Dec 2024 Planned initiation date changed from 13 Nov 2024 to 30 Dec 2024.